{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-191487","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.452198+00:00","generated_at":"2026-05-31T14:12:26.662160+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ResMed Q4 revenue $1.22B (+9% YoY); EPS $1.98; dividend up 10% to $0.53","bullets":["Q4 FY2024 revenue $1,223.2M (+9% YoY, +10% constant currency); gross margin 58.5% (+350 bps).","GAAP diluted EPS $1.98 (+27% YoY); non-GAAP diluted EPS $2.08 (+30% YoY).","Operating cash flow $440M; debt repayments of $300M in Q4; FY2024 operating cash flow $1.4B.","Quarterly dividend increased 10% to $0.53 per share (payable Sept 19, record Aug 15).","Investor Day announced for September 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-191487","json":"https://secwatch.observer/filing/0001193125-24-191487.json","markdown":"https://secwatch.observer/filing/0001193125-24-191487.md","text":"https://secwatch.observer/filing/0001193125-24-191487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312524191487/0001193125-24-191487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312524191487/d805836d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:12:26.662160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}